We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Lillie
Pakzad-Shahabi
l.pakzad-shahabi@imperial.ac.uk
Dr
Matt
Williams
matthew.williams@imperial.ac.uk
Mr
Philip
Badman
p.badman@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasm of breastMalignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Brain metastases (cancer that has spread from a different part of the body to the brain) from breast cancer are a common, yet devastating, complication with survival times of 3 - 5 months from diagnosis. Currently treatment in this group of patients include surgery, stereotactic radiosurgery (SRS), and whole brain radiotherapy (WBRT). However, most patients will either receive WBRT or no treatment and the number of patients who receive surgery and SRS are lower. As the commonest treatment for patients with brain metastasis, which are not treatable with surgery or SRS, is WBRT, we have developed an approach to improve what we think may be more effective. Our approach, dose escalated internal PTV (DE-iPTV)), delivers a higher dose of radiotherapy to the tumour, while delivering less dose to the “normal” brain. We hope that our approach would improve Health-related Quality of Life (HRQoL) by resulting in less side effects.
Through the BEAT-Breast trial we set out to demonstrate the feasibility of DE-iPTV in this group of patients as well as if it is possible to measure their quality of life 8 weeks following their enrolment into the trial.
Alongside this clinical trial, we will work with the Imperial College London Computational Oncology lab to access the NHS England Trusted Research Environment (TRE) through DATACAN. Using linked national cancer data, we can measure the number of patients currently offered WBRT, including survival costs and hospital admissions. In addition, we will collect data on recent historical and contemporary controls in the form of patients undergoing WBRT in the trial centres. That data will be collected locally, pseudonymised and then shared centrally so that we can estimate the outcomes in a contemporaneous patients treated with WBRT from the same centres as are recruiting trial patients.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Radiotherapy;
You can take part if:
You may not be able to take part if:
1. Leptomeningeal disease 2. “Miliary” pattern of metastases: patients with over 15 metastases are excluded (clinician-based decision)? 3. Cystic metastases 4. Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable) 5. Plan for hippocampal-sparing whole brain radiotherapy. 6. Unable to give informed consent. 7. Prognosis less than 3 months 8. Pregnant or nursing women 9. Unable to complete a brain MRI and/or known allergy to gadolinium.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Lillie
Pakzad-Shahabi
l.pakzad-shahabi@imperial.ac.uk
Dr
Matt
Williams
matthew.williams@imperial.ac.uk
Mr
Philip
Badman
p.badman@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by BREAST CANCER NOW .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56229
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
